Raymond James & Associates Has $2.24 Million Position in DaVita Inc. (NYSE:DVA)

Raymond James & Associates lessened its position in DaVita Inc. (NYSE:DVA) by 53.3% during the second quarter, Holdings Channel reports. The institutional investor owned 16,178 shares of the company’s stock after selling 18,430 shares during the quarter. Raymond James & Associates’ holdings in DaVita were worth $2,242,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. 8 Knots Management LLC acquired a new stake in DaVita in the 4th quarter valued at approximately $89,504,000. Doma Perpetual Capital Management LLC acquired a new stake in DaVita in the 4th quarter valued at approximately $53,076,000. Norges Bank acquired a new stake in DaVita in the 4th quarter valued at approximately $36,626,000. Allianz Asset Management GmbH raised its position in DaVita by 63.9% in the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after buying an additional 213,992 shares during the last quarter. Finally, Pinebridge Investments L.P. raised its position in DaVita by 148.8% in the 4th quarter. Pinebridge Investments L.P. now owns 268,601 shares of the company’s stock valued at $28,139,000 after buying an additional 160,630 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the subject of a number of analyst reports. TD Cowen raised their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Truist Financial raised their price target on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. Finally, Barclays raised their price target on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research note on Monday, May 6th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $157.00.

DaVita Stock Performance

Shares of NYSE DVA opened at $150.92 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $156.44. The stock has a 50 day moving average of $142.64 and a 200-day moving average of $138.14. The company has a market capitalization of $12.66 billion, a P/E ratio of 17.15, a P/E/G ratio of 0.80 and a beta of 0.86.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the previous year, the company posted $2.08 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities research analysts predict that DaVita Inc. will post 9.99 EPS for the current year.

Insider Activity at DaVita

In related news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The disclosure for this sale can be found here. Insiders sold 113,601 shares of company stock worth $17,525,449 in the last ninety days. 2.00% of the stock is owned by company insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.